Sarah H.
- Country
- Germany
- Department
- NeuroCure Clinical Research Center- NCRC
Research Overview
- Phase 2a Study to Evaluate the Safety and Efficacy of Empasiprubart as Add-on Therapy to Efgartigimod in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
- Long-Term Safety Evaluation of KYV-101 in Patients with Lupus Nephritis, Systemic Sclerosis, Myasthenia Gravis, Rheumatoid Arthritis, or Stiff Person Syndrome
- Phase 2a Randomized Double‑Blind Placebo‑Controlled Study of Empasiprubart IV Monotherapy in AChR‑Ab Seropositive Generalized Myasthenia Gravis
Data & Insights
Has run more than one trial at 41 of 121 partner sites.
Specializations
Neuromuscular Disorders
The investigator specializes in treating generalized myasthenia gravis (gMG), with particular expertise in both antibody-positive and antibody-negative variants of the condition.
- Acetylcholine receptor antibody seronegative gMG
- Refractory generalized myasthenia gravis
- AChR antibody-positive gMG
The research focus includes novel therapeutic approaches for various presentations of myasthenia gravis.
Immunotherapy Development
Actively involved in evaluating innovative immunological treatments for neuromuscular conditions, including targeted antibody therapies and cellular approaches.
- FcRn antagonist therapies
- Anti-CD19 CAR T-cell therapy
- Novel antibody-based treatments
Expertise extends to investigating both intravenous and subcutaneous administration routes for immunological therapeutics.
Clinical Assessment
Specializes in evaluating treatment outcomes using standardized clinical assessment tools for neuromuscular disorders.
- MG-ADL scale implementation
- Treatment efficacy evaluation
- Safety profile assessment
Focuses on measuring therapeutic impact on daily living activities and quality of life in gMG patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.